Insmed Inc (NASDAQ:INSM)
| 28.01 Delayed Data As of Aug 08 |  +0.20 / +0.72%Today’s Change | 16.41 Today|||52-Week Range 34.44 | +2.83% Year-to-Date |
Latest INSM News | Press Releases
| Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates Aug 04 / Zacks.com - Paid Partner Content | Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know Jul 28 / Zacks.com - Paid Partner Content |
| Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline Aug 01 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 27.75 |
| Today’s open | 28.00 |
| Day’s range | 27.23 - 28.74 |
| Volume | 3,558,789 |
| Average volume (3 months) | 1,165,292 |
| Market cap | $3.3B |
Data as of 3:59pm ET, 08/08/2022
Growth & Valuation
| Earnings growth (last year) | -28.67% |
| Earnings growth (this year) | +12.54% |
| Earnings growth (next 5 years) | +7.60% |
| Revenue growth (last year) | +14.63% |
| P/E ratio | NM |
| Price/Sales | 16.20 |
| Price/Book | 8.04 |
Competitors
| ---- | ||
| FOLDAmicus Therapeutics ... | +0.36 | +2.96% |
| GLPGGalapagos NV | -0.60 | -1.10% |
| CCXIChemoCentryx Inc | +0.37 | +0.73% |
Data as of 4:00pm ET, 08/08/2022
Financials
| Next reporting date | November 3, 2022 |
| EPS forecast (this quarter) | -$0.88 |
| Annual revenue (last year) | $188.5M |
| Annual profit (last year) | -$434.7M |
| Net profit margin | -230.63% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bridgewater, New Jersey |
Forecasts
